11 drug candidates were initially screened by the Company in globally accepted in vivo animal models for 4 new disease areas:
Non-alcoholic Steatohepatitis (NASH)
Chronic Kidney Disease (“CKD”)
Inflammatory Bowel Disease (IBD)
Idiopathic Pulmonary Fibrosis(IPF)
Initial studies showed that a number of the 11 drug candidates either performed equal to or better than the positive controls in each of the animal studies. Subsequent in vivo studies have confirmed their efficacy.
All Algernon research studies were conducted by 3rd party contract research organizations. The studies were well designed with proper positive controls, using the currently accepted gold standard for treatment in the disease being screened.
Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).
Chronic Kidney Disease
Inflammatory Bowel Disease
Idiopathic Pulmonary Fibrosis
Christopher J. Moreau, Chief Executive Officer
Mark Williams PhD MBA, Chief Science Officer
General Inquiries: firstname.lastname@example.org
Head Office: Suite 915 – 700 West Pender Street Vancouver, BC, Canada V6C 1G
Shares Outstanding: 90.0M Fully Diluted: 141.6M